summari tuesday host bi-annu investor
meet nyc expect lower top bottom line
long-term growth goal compar goal provid
previou investor meet two year ago expect
previous ep growth per year versu doubl digit ep
bp oper leverag per year versu prior goal
bp per year clearli updat long-term guidanc
realist compar prior goal howev fallen short
oper leverag goal past year given
recent misstep leverag would prefer wait see better
execut margin get construct
share especi light recent run-up share
strategy-wis compar two year ago saw greater
emphasi technolog innov less focu servic
drive top-line addit saw greater focu execut
set realist goal meet beat
pipelin front potenti larg pipelin product
robot new launch rel light view
tweak model close reflect longer-
term financi commentari particularli relat oper
margin improv fy beyond leav fy
adj ep estim unchang lower fy estim
report maintain price target
base cy ep estim
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani prioriti stock list
compani data secur llc estim reuter
sustain organ growth driven primarili innov global
see sustain annual organ revenu growth long-term driven combin
innov therapi global notabl emerg market growth broad
pipelin product across four busi expect drive growth near longer-
term wed note vantag point major top-lin growth catalyst arent expect come
market fy later look variou busi cvg cardiac vascular
group mitg minim invas therapi group rtg restor therapi group expect
grow in-lin overal corpor averag diabet expect grow
broader averag geographi expect develop market grow organ growth
rang em emerg market expect grow low double-digit continu view
em singl largest opportun med-tech term econom valu remain
commit introduc new busi model help drive share gain increment revenu growth
stabil price notabl exampl includ mdt tyrx risk-shar arrang cryoballoon
outcom agreement regard inorgan growth manag said continu look tuck-in
 supplement top-lin
top-lin focu therapi innov contrast investor meet felt place
notic greater emphasi therapi innov year meet evidenc ceo omar
ishark open remark mdt strategi innov util three prong approach continu
innov invent disrupt mdt continu innov strategi mean enhanc
outcom econom valu exist product intelli resolut onyx contrast
defin invent creat develop new therapi creat new market reveal linq
solitair stent retriev disrupt signifi therapi disrupt exist med-tech
market micra leadless pacer pump arctic front advanc cryoballoon clear
global econom valu still import part storyboth near long-term
howev felt like discuss year event deliber center therapi
annual underli op margin improv center enterpris excel initi
outlin underli oper margin expans goal annual long-term
realist view compar previou long-term guidanc bp per year wed
note expect in-lin fiscal guidanc ex-fx well-below
aggreg target oper margin improv ex-fx provid compani
investor day look drive major margin improv enterpris
excel initi introduc earlier year program design off-set price
pressur enabl reinvest drive oper margin expans manag continu
expect save fy
expect adjust ep growth plan period bottom-lin outlin
long-rang target adj ep growth durat plan period assum modest
currenc volatil note growth also serv compani annual goal
manag said could year cant off-set neg impact fx lead ep growth
fall short target howev also said could year currenc tailwind
epsin would manag adj ep growth fiscal guidanc
target convers year meet ceo cfo
highlight free cash flow convers prioriti entir organ focu
drive account across busi region mdt averag convers
slightli peer group factor improv convers includ hold a/p term
optim inventori close scrutin capit expenditur need addit part cf
convers focu one-third mdt annual compens plan tie target revenu
ep factor start
continu target return sharehold consist plan
analyst day target return least sharehold return sharehold
compris dividend compani plan maintain pay-out ratio opportunist
share repurchas part increas focu sharehold return one-third mdt long-term
perform plan tie rel total sharehold return start manag
target double-digit sharehold return go forward compris ep dividend
debt pay longer prioriti capit alloc meet manag note
complet cov-rel debt last year debt pay longer prioriti capit
alloc plan access cash global vs post-cov believ
well posit execut balanc capit deploy plan specif compani focus
consist drive dividend growth in-lin earn growth invest tuck-in acquisit
buy-back share opportunist revenu growth accret acquisit exclud
mdt current organ sale growth target earn perspect manag expect
absorb earn dilut result typic tuck-in deal intern compani evalu
portfolio determin whether invest growth invest sustain busi review busi
improv divestitur context target return invest capit
note target embed
manag long-term compens plan last year although compani meet
target
cvg cardiac vascular group
attribut cvg growth outlook under-penetrated natur variou end market strong
competit posit strategi target high-growth categori tavr long-term cvg
expect deliv growth in-lin corpor averag growth despit weight averag
market growth rate wamgr figur detail look cvg end-
market product pipelin
tavr still view biggest growth driver cvg previou market estim unchang
manag said continu view tavr franchis singl largest growth driver
cvg franchis come year consist compani said two year ago still
expect world-wide tavr market fy impli low mid-
teen growth compound-annual-growth-rate compound annual growth rate mdt tavr platform driven market
growth past sever quarter behind expans new indic intermedi risk
new product introduct evolut manag remain confid compani competit
posit look ahead expect introduc cadenc new tavr product everi month
low-risk tavr data target see major catalyst tavr
market today meet said target readout low-risk tavr trial american
colleg cardiolog march wed note compani previous guid less specif
time-frame spring believ present low-risk studi ew
would import posit awar perspect major catalyst overal tavr
market provid studi posit tavr expect
continu favor replac transcathet mitral therapi manag continu
bullish opportun within transcathet mitral valv space believ broader
market could grow roughli aggreg fy manag expect evid
support use intervent secondari function mr lead increas penetr
transcathet therapi replac technolog prefer procedur long-term
continu bullish replac therapi given potenti provid
patients/clinician reliabl complet reduct mitral regurgit mr said
still see valu toolbox approach treat mr manag said current evalu two
differ mitral repair solut one intern one extern partner
intrepid updat posit also provid hand posit updat intrepid tmvr devic
manag said us pivot studi apollo enrol well site activ
compani comment seen improv patient screen yield ratio
help pace enrol also note continu make progress develop
transseptal/transfemor deliveri system first-in-human use expect back half fy
view complementari therapi htn though fda approv still year
commerci time remain year away beyond fy believ opportun
play import role treat patient htn hypertens particularli light medic
complianc issu estim patient htn today number
expect exceed announc past april receiv approv fda
begin us pivot trial compani symplic spyral devic spyral htn pivot trial
random sham-control studi enrol off-m patient site across
 europ australia japan manag said today alreadi site activ
patient random manag expect trial take year enrol guid fda approv
beyond fy also plan run larger studi med popul studi
current develop import on-m popul repres bigger
commerci opportun
pipelin continu center around micra ev-icd low-pow said work
develop sever deriv micra single-chamb pacemak today estim current
micra product address total address market despit nich role micra
import growth driver cardiac rhythm manag busi compani said micra
exit annual well-ov sale next iter mdt micra technolog
compani micra av devic dual-chamb pacemak commerci approv expect
manag estim product would treat total address market meaning
increas avail opportun today high voltag remain focus develop
ev-icd extravascular implant cardiovert defibril compani believ address
limit associ today s-icd subcutan implant cardiovert defibril
devic infect rate lack anti-tachi pace expect begin first chronic implant
though us/ou commerci releas expect beyond
manag remain confid reveal linq growth prospect despit slowdown
expect broader insert cardiac monitor icm market grow mid-teen
growth mdt linq declin due competit trial abt confirm rx
devic manag remain confid compani icm technolog manag note
price confirm rx roughli discount led initi trial expect regain
least lost share trial subsid manag also said linq possess better accuraci
confirm rx superior batteri life plan introduc linq ii wafer scale platform
time-frame next-gen product featur year batteri life bluetooth connect
improv accuraci vital sign sensor may applic addit indic
expect af ablat market expect grow hsd like conserv expect
af atrial fibril ablat market grow high-single-digit
consist mid-teen growth weve seen past sever quarter accord
market model ultim chalk disconnect manag conservat especi light
recent cabana result present hr heart rhythm societi past month longer
term continu expect af market grow low mid-teen least next coupl
year behind new technolog radiofrequ rf contact forc sens balloon ablat
cathet mdt cryo bsx apama jnj rf balloon well increas awar
diagnosi af regard pipelin work next-gen cryoballoon system
abil treat variabl vein anatomi electrod navig time
next-gen system provid explor puls field ablat treatment
af though understand therapi earli stage develop
lvad updat larg expect mdt lvad left ventricular assist devic busi grew faster
market fiscal driven destin therapi dt indic hvad devic fy
expect receiv thoracotomi indic fda introduc new control offer
remot patient monitor background thoracotomi minim invas approach
implant lvad compar tradit sternotomi approach propon believ
thoracotomi result fewer patient complic faster recoveri time long-term continu
work mvad devic also fulli implant lvad technolog regard market
expect expect lvad market grow high-singl digit
target new geographi and/or indic dcb/endoven growth estim
hold posit global endovenous/dcb drug-coat balloon market
expect grow high-singl low-doubl digit growth next year dcb
see market opportun nearli doubl admir driven geograph expans
japan china new indic enrol complet us av access
eu btk trial recent reimburs chang dcb treat sfa superfici femor arteri
hurt us opportun make new indic market even import longer term
growth keep mind competitor launch av arterioven indic us nearli
year ago seen meaning growth dcb franchis btk knee
recent confirm track complet pivot us trial file fda releas
data later year endoven estim global market grow
current venas closur system compani focus expand us payor coverag drive
greater adopt deep venou market start abr venou stent pma pre-market
applic trial us launch devic ou
spinal cord stimul spine recent driven turnaround rtg attribut
strategi priorit innov high growth market see figur focu continu
go forward estim mix high growth product continu rise less
today nearli see figur rtg pipelin long-term rtg expect
deliv growth in-lin corpor averag growth despit weight averag market growth
rate wamgr
enabl technolog spine growth go forward spine therapi enabl
technolog repres address market grow mid-singl digit compound-annual-growth-rate
hold market posit compani clear spine strategi driven enabl
technolog mazorx drive implant pull order drive util compens
acquisit cost mazorx return custom commit increment implant busi
year period compani also bring two meaning enhanc mazorx drive
increment pull believ enhanc showcas north american spine
societi nass medic meet sep lo angel ca first integr
stealthstat navig mazorx allow bridg gap competitor would
also enabl provid fulli packag offer custom integr navig surgic
plan robot power instrument second implant integr mazorx
navig featur shut custom specif use implant light
larg stealthstat instal base would expect function benefit
elsewher remain focus speed scale new launch area degen
complex spine compani spine financi also improv mid-singl digit growth
expect next five year lower cog better abil protect price competit market
enabl technolog worth note increas percentag us spine busi
contract year ago today expect account
tend higher util note implant growth averag account look
ahead expect spine therapi enabl technolog segment gener one third
compani rtg segment growth
brain specialti therapi drive half rtg growth brain specialti
therapi repres combin address market hold market posit brain
therapi includ brain modul neurovascular csf cerebrospin fluid critic care
estim market deliv low-doubl digit growth gener one-third
mdt rtg segment growth neurovascular highlight key growth driver
segment whole pave way market develop effort full portfolio
product compani offer solitair revascular devic ischem stroke pipelin flow
divers hemorrhag stroke expect launch riptid aspir system fda clear
new react cathet expect near futur specialti therapi includ pelvic health ent ear nose
throat transform solut estim market deliv mid-singl digit
growth gener one-fifth mdt rtg segment growth
signific growth momentum neurovascular ceo omar ishrak highlight innov technolog
mdt stroke busi help expand/develop stroke market past nearli year
today believ leader global stroke market grew last year
compani remain activ help develop emerg servic rout patient care pathway
protocol key factor drive continu market growth believ well posit
neurovascular comprehens portfolio includ flow divert stent retriever/aspir
intravascular devic anticip fda clearanc new react cathet immin
launch already-approv riptid pump mark first entri aspir market
compani also develop next-gener flow divert expect reach market
year addit manag highlight cross-sel opportun reveal linq
help hospit detect/manag stroke risk af atrial fibril patient
pain therapi drive roughli rtg growth pain therapi repres
address market grow high-singl digit cargr hold market
posit compani sub-seg includ drug deliveri intervent spine
driven turnaround pain busi recent grew versu full
year note intelli implant neurostimul key driver trend given
technolog advantag world smallest implant neurostimul offer hour
recharg time retain batteri capac year pair evolv workflow give
surgeon option use either low- high- dose stimul snapshot provid access patient
activ data compani expect increment data support therapi releas north
american neuromodul societi nan januari la vega nv overal
build leadership pain categori increas patient accept miniatur implant reduc
procedur manag time batteri technolog visual program improv patient
outcom patient-specif algorithm interestingli leader mdt busi state
meet longer expect share donor go forward expect
busi growth doubl digit rate
mitg featur robust pipelin see figur aim supplement tuck-in acquisit
appropri compani substanti focu em categori expect continu
go forward long-term mitg expect deliv growth in-lin corpor averag growth
despit wamgr figur closer look mitg end-market
mitg target mid-single-digit growth mitg repres busi unit
within approxim market recal mitg compris surgic innov
si respiratori gi gastrointestin renal sold patient deep vein
thrombosi nutrit insuffici busi juli expect grow mitg sale
mid-singl digit three six key growth driver includ open mi
minim invas surgeri emerg market advanc paramet informat expect
deliv roughli futur mitg growth three key growth driver gastrointestin
diseas renal diseas specialti diversif diagnost lung less invas gynecolog
expect contribut approxim growth remain growth
expect come core market look ahead expect mix six high growth
driver increas mitg revenu current also robust
pipelin product launch year ahead key launch
includ robot colorect stapler sonicis platform updat
open surgeri mi repres compel opportun within mitg estim
open surgeri account procedur repres market mi minim
invas surgeri procedur volum also repres market robotic-
assist surgeri constitut less procedur volum us repres market
view open mi convers signific opportun avail even contribut
robot manag believ potenti open surgeri convert
mi note even convers would translat increment opportun
said manag acknowledg barrier convers limit infrastructur surgic
skill incorrect percept mi expens limit awar mi benefit open
surgeri highlight advanc stapl portfolio market opportun
leader drive improv surgic outcom minim procedur variabl compani
like extend leadership launch circular stapler could expand usag colorect
procedur also expect continu uptak ligasur technolog see nice adopt
head neck surgeri among other faster seal time
robot launch push pre-clin test underway surgic robot
platform current undergo pre-clin test anticip advanc platform clinic
test target full launch compani previous aim
market one-year delay result final softwar hardwar integr test
took longer anticip sinc work optim function improv reliabl
analyst day note revenu robot platform could add
mitg growth translat estim sale also indic time
would target india first note today convers regulatori bodi
us europ determin path forward compani robot invest began januari
largest strateg invest mitg current support employe
locat remain commit platform stand benefit given low penetr
market estim robot current account procedur us less
outsid us ou look ahead compani aim introduc platform
low-cost easili upgrad solut similar laparoscopi drive util reduc
econom barrier associ robot surgeri goal offer natur step forward versu
laparoscopi build capabl treat wide array procedur stapl vessel seal etc
light competit landscap disclos littl respect platform design go
diabet expect outpac overal sale growth diabet busi grew
despit essenti flat year manag expect diabet
major busi unit outpac overal corpor sale growth target organ next
year growth stem sensor pull-through patient pump renew convers multi-daili
inject mdi patient new insulin pump well entri stand-alon cgm
market core diabet busi aim advanc insulin manag compris bulk mdt
current diabet revenu new player mdi segment recent launch person
cgm current hold share categori compani also target ndt non-
intens diabet therapi categori hold share modest categori figur
detail look diabet end-market product pipelin
expect drive revenu growth exist new patient hold
share global insulin pump categori manag note market penetr still
low suggest still meaning growth opportun ahead specif compani
believ launch year ago first hybrid close loop system help
convert patient need multipl insulin inject daili insulin pump compani estim
mdi patient move add annual revenu addit note
one-third us instal patient base use cgm continu glucos monitor number
increas nearli two-third patient renew upgrad translat increas annual
revenu per patient estim instal patient base renew
year yield increment revenu opportun come year sinc launch year ago
us gain pt market share us mark highest share posit nearli
decad compani track launch eu believ
step closer develop ultim fulli closed-loop system artifici pancrea
near-term next-gener upgrad includ bluetooth connect smartphon enabl new
harmoni sensor integr infus
enter fast grow mdi market person solut estim
type patient global requir multipl daili inject mdi compani launch
first stand-alon cgm guardian connect sugar iq intend provid predict alert
insight keep patient within desir glycem rang sugar iq develop ibm watson
ai artifici intellig -base assist provid insight insulin inject food intak
trend monitor glucos level busi develop softwar improv glucos
alert current hour compar minut current competitor
meaning improv patient glycem control manag estim stand-alon cgm market may
doubl even tripl current size next year potenti captur
compound-annual-growth-rate cvgmarket positioncontribut cvg digits/ -doubl high-growth matur compani report secur drive linq trurhythmvenas closur systemintrepid tmvr corevalv evolut corevalv evolut mmsymplic spyralhvadmicra av vdd af puls field ablationmicra reimbursementarct front advanc extravascular icdendur heli-fx short neckpolari bluetooth mvadvisia afsmartsyncmicra expansionresolut onyxlinq ii bluetooth waferscal horizon next- tavi avalu surgic valveadmir dcb -avfnext resolut onyxazur wireless pacemakertyrx wrap-ittavr risk percepta crt-p quadtavr bicuspidadmir dcb below-the-kneecorevalv evolut ir cohortlvad thoracotomylvad destin therapi compani report secur llc medtron plc
cagrmarket positioncontribut rtg growthbrain therapi enabl compani report secur llc exclud orthoped solutionsmarketmdtlaunch drive xcranial mount dbsinject tibial nerv stealth autoguidemedina intrasaccular deviceinfinitymicrostimul sacral stratospher diverterartic-l titanium interbodyriptid aspir systemdirect db leaddiamond-lik coat drug pumpsab tlifstealth spinal cranial entneuromodul programmersdb primari cell sens o-arm systement power consol visualas compact systemvisualas ce markdb epilepsi usinfus clinic indic expansionosteocool bone anatomi compani report secur llcmazor stealth technolog integrationtransform innovationmeaning iterationscal platformexpand indicationsintelli pain ulat programm platform medic technolog
launch drive stapl systemsonicis platform updatecapnostream oem monitorligasur vessel sealingmultitherapi blood purif systemendo-bronchi ablat cathetercapnostream portabl respiratori monitorcolorect staplernext-gener dialyzeremprint sx ablat systemmicrostream sampl linesra instrument enhanc -stapler energyparieten ds composit meshrobot assist surgeri ra platformversaon fascial closur system compani report secur llcgrowth cagrlead market positioncontribut mitg growthadvanc digitsyemerg digitsyadvanc paramet digitsygastro-intestin digitsyren digitsyspeci digitsyoth compani report secur llc exclus group growth plc
growth driverscategori market compound-annual-growth-rate loop standard-of-careincreas cgm attach rate drive mdi convers expansionlaunch stand-alon cgm smart cgm system focus outcomesexpans type increas diagnost cgm glucos vital sign manag compani report secur drive connectivityauto bolusingmio advancedharmonycombin set extend ai cloudsugar iq w/insightssugar iq hypo predictionimprov sensorsguardian connectsugar iq dose assistantglucos predictionmedtron iprointellig therapi recommend time coachingperson guidancemedtron envis timemedtron envis pro compani report secur llcmdisaimndt medic technolog
price target nc
price target assum cy cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ deliv averag organ growth due lull major new product launch
combin competitor headwind
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
plc incom statementin million except per share datafisc year end etot net currenc y-i expensesresearch oper incomenet interest expens amort incom tax incom adj continu year-to-year incom year-to-year incom dilut share year-to-year adjust pmr divestitur not-adjustedsourc compani report secur llc estim plc
